elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q34781122-5C5F1479-4313-407B-8F39-FC803D90C638
Q34781122-5C5F1479-4313-407B-8F39-FC803D90C638
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34781122-5C5F1479-4313-407B-8F39-FC803D90C638
A framework for genomic biomarker actionability and its use in clinical decision making
P2860
Q34781122-5C5F1479-4313-407B-8F39-FC803D90C638
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34781122-5C5F1479-4313-407B-8F39-FC803D90C638
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
812a638f4e7e4651cc9ba5c9356576df87ee8da2
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.